

Product specification ANTIBODY

2025-02-24

Anti-h NMP22 R12509 SPTN-5

Product overview

Catalog number 140055

Specificity Antibody recognizes human nuclear matrix protein 22 (NMP22)

Description Recombinant mouse antibody, cultured *in vitro* under conditions free from

animal-derived components.

Product buffer solution 50 mM Na-citrate, pH 6.0, 0.9 % NaCl, 0.095 % NaN₃ as a preservative

Shelf life and storage Unspecified, storage at 2–8 °C

 $\begin{tabular}{l} Subclass & IgG_1 \end{tabular}$

Analyte description NMP22 is part of the nuclear mitotic apparatus which is responsible for the

distribution of chromatin to daughter cells during mitosis. NMP22 can be used as tumor marker. Particularly, the levels of NMP22 are elevated in bladder cancer and it can be used in the early diagnosing and monitoring

of bladder cancer.

Parameters tested on each lot

Product appearance Liquid, may turn slightly opaque during storage

Product concentration 5.0 mg/ml (+/-10 %) (A280 nm, 1 mg/ml, 1 cm = 1.7)

Immunoreactivity 80–120 % compared to the reference sample in an FIA test

IEF Profile 6.7–7.5

Purity ≥ 95 %

Kinetic parameters

Association rate constant 4.9 x 10⁴ 1/Ms

Dissociation rate constant Does not dissociate under conditions used

Affinity constant Not applicable (N/A)

Determination method BLI (Octet RED96e)

Determination antigen Recombinant Nuclear Mitotic Apparatus Protein 1, Cloud-Clone Corp.

(Cat RPC332Hu02)





Product specification ANTIBODY

2025-02-24

Cross-reactivities Not Determined (N/D)

Epitope Within amino acids 1-212 of NMP22

Pair recommendations

		DETECTION			
		R12501	R12508	R12509	R12510
CAPTURE	R12501	-	+	+	+
	R12508	-	-	+	+
	R12509	+	+	+	+
	R12510	+	+	+	+

Following pairs are especially recommended for the below mentioned assays:

CLIA: R12508 (capture) – R12510 (detection) and R12510 (capture) – R12510 (detection)

Please note that pair recommendations are based on results obtained by our laboratory. Equally good results may be obtained using other pairs and therefore these recommendations are only indicative.

Platforms tested FIA, CLIA

Antigens tested N/D

Product stability TEMPERATURE, TIME RESULT

-70 °C, 21 days OK -20 °C, 21 days OK +4 °C, 21 days OK

+35 °C, 21 days Minor charge alterations +45 °C, 7 days Minor charge alterations

Stability testing is performed in the product buffer to see whether different temperatures affect the antigen binding, charge or composition of the antibody. Please note that the shelf life given on the first page is based on real time stability testing at 2–8 °C in the product buffer.

Miscellaneous -

References -

Oy Medix Biochemica Ab

FI-02180 Espoo, Finland

Klovinpellontie 3,

